Net Income

Stonegate Investment Group's $6 billion move to NewEdge's 'Pillar Channel' highlights a new model for advisor monetization and client-centric growth.

Alzheon's pill ALZ-801 shows promise in early AD patients with high genetic risk, offering a potential path that avoids the brain swelling seen in IV drugs.

Edgewise Therapeutics' drug sevasemten shows unprecedented functional stability in Becker muscular dystrophy, a pivotal shift for a disease with no treatments.

After selling assets and raising cash, Q32 Bio focuses all its resources on bempikibart, a novel drug for hair loss, with pivotal data due in 2026.

A new report finds 80% of cyber incidents stem from stolen credentials, with AI and trusted work apps like Teams and Zoom becoming the hacker's top tools.

Glasswall's new AI solution, Foresight, promises to predict unknown malware by analyzing file DNA, shifting security from reactive to proactive defense.

Uranium Energy Corp reports a strong quarter with new mine completion, robust finances, and a strategic push to build a fully domestic nuclear fuel cycle.

A new partnership aims to deploy over a billion dollars into restoring global ecosystems, betting on high-integrity carbon credits to fund the fight for nature.

As India's retail investor base explodes, a decade-old zero-brokerage model gets a high-tech upgrade, challenging rivals to offer more than just low costs.

A new study reveals Canadians lost billions in wages waiting for care. This is the staggering personal and economic cost of the nation's healthcare queues.

OSE Immunotherapeutics confirms Marc Le Bozec as CEO, betting on his turnaround expertise to navigate market pressures and commercialize its key therapies.

Sports education giant Leifras expands to its 46th prefecture, partnering with J.League's Blaublitz Akita to launch a unique youth soccer school.

A new line of ultra-pure proteins with endotoxin levels 10x below the standard could revolutionize advanced therapies and fix a key source of error in science.

For the fourth straight year, EPAM is named a top IT vendor in the Netherlands, driven by exceptional client satisfaction and a strategic focus on AI.

Struggling with inconsistent income? A new wave of business strategy uses hard data to build predictable client systems, leaving 'hustle culture' behind.

After 15 years without new therapies, Tonix Pharma's TONMYA enters the fibromyalgia market with a unique sublingual drug and an ambitious commercial plan.

As Cal-Maine preps its Q3 report, investors watch if its pivot to prepared foods and specialty eggs can offset plunging prices and new avian flu threats.

With its finances on a knife's edge, Faraday Future is pitching a bold new vision of AI robots and mass-market EVs to skeptical investors. Can it deliver?

AEON Biopharma hires a seasoned CFO to navigate FDA trials and financial hurdles as it aims to launch its BOTOX biosimilar into a lucrative market.

Transcat appoints decorated industrial leader Jaime Irick as its new CEO, signaling a strategic pivot toward accelerated growth and market expansion.